https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Kintara_Therapeutics%2C_Inc.Kintara Therapeutics, Inc. - Revizia istoricului2026-04-04T10:41:25ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Kintara_Therapeutics,_Inc.&diff=427771&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Kintara Therapeutics, Inc. listata cu simbolul US.KTRA ==Descriere companie== Kintara Therapeutics, Inc. (www.kintara.com) is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing two late-stage, Phase III-ready therapeutics. The Company's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent,...2024-09-18T18:08:26Z<p>Pagină nouă: Pagina dedicata companiei Kintara Therapeutics, Inc. listata cu simbolul US.KTRA ==Descriere companie== Kintara Therapeutics, Inc. (www.kintara.com) is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing two late-stage, Phase III-ready therapeutics. The Company's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent,...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Kintara Therapeutics, Inc. listata cu simbolul US.KTRA<br />
<br />
==Descriere companie==<br />
Kintara Therapeutics, Inc. (www.kintara.com) is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing two late-stage, Phase III-ready therapeutics. The Company's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The Company is carrying out various clinical trials on brain tumor and solid tumor.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.KTRA" /><br />
<br />
==Ultimele stiri despre Kintara Therapeutics, Inc. (US.KTRA)==<br />
<dynamicpagelist><br />
category=US.KTRA<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.KTRA]][[Categorie:Stiri despre companii]]</div>Admin